Clinical-stage biopharmaceutical company developing antibiotic drugs for bacterial infections, led by its lead candidate ibezapolstat for C. difficile infection.
Phase 3 registration planning under FDA Type C guidance
Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
Acurx has received FDA guidance from a July 2026 Type C meeting on ibezapolstat's Phase 3 clinical program, including the potential for a single-Phase 3-trial registration plan and a trial design supporting both treatment and reduction of r
President and Chief Executive Officer